N-[(1R,3S)-3-[(8aS)-6-oxo-1,3,4,7,8,8a-hexahydropyrrolo[1,2-a]pyrazin-2-yl]cyclohexyl]-4-fluoro-7-methyl-1H-indole-2-carboxamide

ID: ALA5195440

PubChem CID: 168287143

Max Phase: Preclinical

Molecular Formula: C23H29FN4O2

Molecular Weight: 412.51

Names and Identifiers

Canonical SMILES:  Cc1ccc(F)c2cc(C(=O)N[C@@H]3CCC[C@H](N4CCN5C(=O)CC[C@H]5C4)C3)[nH]c12

Standard InChI:  InChI=1S/C23H29FN4O2/c1-14-5-7-19(24)18-12-20(26-22(14)18)23(30)25-15-3-2-4-16(11-15)27-9-10-28-17(13-27)6-8-21(28)29/h5,7,12,15-17,26H,2-4,6,8-11,13H2,1H3,(H,25,30)/t15-,16+,17+/m1/s1

Standard InChI Key:  UYSOGWLYOSWGNI-IKGGRYGDSA-N

Molfile:  

 
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
   -4.2703   -1.2546    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5557   -0.8423    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8438   -1.2543    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8438   -2.0794    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5539   -2.4912    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.2703   -2.0831    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0591   -2.3344    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0591   -0.9993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5741   -1.6669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5557   -0.0172    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5539   -3.3164    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7488   -1.6669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3363   -0.9523    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3363   -2.3816    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.4888   -0.9523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9014   -0.2377    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7266   -0.2377    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1392   -0.9523    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7266   -1.6669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.9014   -1.6669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1392    0.4769    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.7266    1.1915    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1392    1.9061    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9644    1.9061    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.3770    1.1915    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9644    0.4769    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1840    1.3630    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.5165    2.5193    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2703    2.1836    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3029    3.3164    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8620    0.5239    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  4  7  1  0
  3  8  1  0
  8  9  2  0
  9  7  1  0
  2 10  1  0
  5 11  1  0
  9 12  1  0
 12 13  1  0
 12 14  2  0
 15 13  1  1
 16 15  1  0
 17 16  1  0
 18 17  1  0
 19 18  1  0
 20 19  1  0
 15 20  1  0
 17 21  1  1
 22 21  1  0
 23 22  1  0
 24 23  1  0
 25 24  1  0
 26 25  1  0
 21 26  1  0
 25 27  1  0
 24 28  1  0
 28 29  1  0
 29 27  1  0
 28 30  2  0
 25 31  1  6
M  END

Alternative Forms

1. Parent:

   

   ALA5195440

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 412.51

Molecular Weight (Monoisotopic): 412.2275

AlogP: 2.96

#Rotatable Bonds: 3

Polar Surface Area: 68.44

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 8.16

CX LogP: 2.13

CX LogD: 1.30

Aromatic Rings: 2

Heavy Atoms: 30

QED Weighted: 0.81

Np Likeness Score: -1.03

References

1. Alford JS, Lampe JW, Brach D, Chesworth R, Cosmopoulos K, Duncan KW, Eckley ST, Kutok JL, Raimondi A, Riera TV, Shook B, Tang C, Totman J, Farrow NA..  (2022)  Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies.,  13  (7.0): [PMID:35859865] [10.1021/acsmedchemlett.2c00167]

Source

Source(1):

• Scientific Literature